What Is Ogsiveo Approved For?
Ogsiveo (nirogacestat) is approved by the FDA for treating desmoid tumors in adults. These are rare, non-cancerous soft tissue tumors that grow near muscles, tendons, or bones. The approval came in November 2023 based on the DeFi trial, which showed Ogsiveo shrank tumors in 41% of patients versus 8% on placebo.[1][2]
How Does It Work Against Tumors?
Ogsiveo inhibits gamma secretase, an enzyme that fuels tumor growth by activating the Notch signaling pathway. In desmoid tumors, this pathway drives uncontrolled cell proliferation. Clinical data confirmed tumor volume reductions averaging 33% after 15 months.[1]
Is It Effective for Other Tumors or Cancers?
No approvals exist for other tumors. It's specifically for desmoid tumors, which are benign but can be aggressive and painful. Ongoing trials explore combinations with immunotherapies for ovarian cancer and other solid tumors, but results are pending.[2][3]
When Does the Ogsiveo Patent Expire?
Key U.S. patents on nirogacestat expire between 2037 and 2041, covering the drug substance and methods of use. No Paragraph IV challenges are listed yet on DrugPatentWatch.com.[4]
Common Side Effects Patients Report
Fatigue (72%), diarrhea (68%), nausea (48%), ovarian issues like cyst formation (up to 75% in women), and low blood cell counts occur frequently. Serious risks include lung inflammation and liver enzyme elevation.[1][2]
[1]: FDA Approval Summary - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nirogacestat-desmoid-tumor
[2]: SpringWorks Therapeutics Prescribing Information - https://www.ogsiveo.com/
[3]: ClinicalTrials.gov (NCT05889224) - https://clinicaltrials.gov
[4]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/OGSIVEO